Investors & News / Media Coverage / Media Coverage Year None202420222020201920172016 May 10, 2024 Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results Apr 23, 2024 Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors Apr 10, 2024 FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma Apr 10, 2024 Lisata wins FDA orphan drug status for bone cancer candidate Jul 06, 2022 CEND-1 Offers Hope in Advanced Pancreatic Cancer Oct 15, 2020 Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study May 15, 2020 Cell therapy improves coronary flow reserve in coronary microvascular dysfunction Jan 15, 2020 Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020 Dec 05, 2019 Dr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD Nov 21, 2019 Single-Injection Cell Therapy Relieves CMD Symptoms First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last » Print Page RSS Feeds Email Alerts
Year None202420222020201920172016 May 10, 2024 Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results Apr 23, 2024 Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors Apr 10, 2024 FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma Apr 10, 2024 Lisata wins FDA orphan drug status for bone cancer candidate Jul 06, 2022 CEND-1 Offers Hope in Advanced Pancreatic Cancer Oct 15, 2020 Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study May 15, 2020 Cell therapy improves coronary flow reserve in coronary microvascular dysfunction Jan 15, 2020 Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020 Dec 05, 2019 Dr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD Nov 21, 2019 Single-Injection Cell Therapy Relieves CMD Symptoms First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last »
May 10, 2024 Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Oct 15, 2020 Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study
Jan 15, 2020 Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020
Dec 05, 2019 Dr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
